Relationship Between 8-iso-Prostaglandin-F_2a and Predicted 10-Year Cardiovascular Risk in Hypertensive Patients

• DOI: 10.20944/preprints202502.0388.v1
• Publication Date: 2025-02-07T02:38:16Z
• Authors: Giulio Geraci; Alessandra Sorce; Luca Zanoli; Giuseppe Cuttone; Vincenzo Calabrese; Francesco Pallotti; Valentina Paternò; Pietro Ferrara; Ligia J. Dominguez; Riccardo Polosa; Giuseppe Mulè; Caterina Carollo

8-iso-prostaglandin-F2α (8-iso-PGF2α) is a recognized marker of oxidative stress. Previous studies suggested that 8-iso-PGF2α plays an important role in the pathogenesis of hypertension and cardiovascular (CV) diseases. However, limited data exist on the prognostic role of 8-iso-PGF2α in hypertensive patients undergoing primary prevention. The aim of this study was to assess the relationship between 8-iso-PGF2α and 10-year CV risk, as predicted by validated equations in hypertension patients without CV diseases. Materials and methods. A total of 432 individuals aged 40-75 years were enrolled. Plasma 8-iso-PGF2α was assessed through ELISA method. CV risk was calculated by using the Framingham Risk Score (Fr-S) and the Atherosclerosis Cardiovascular Disease Risk Score (ASCVD-S). Low, moderate, or high CV risks were defined according to validated cutoffs. Results. Individuals with higher CV risk had significantly greater 8-iso-PGF2α values compared to those with low or moderate CV risk (p<0.001). 8-iso-PGF2α correlated strongly with Fr-S and ASCVD-S in the entire population and in patients with normal renal function (all p<0.001), but not in patients with eGFR<60 mL/min/1.73m2. These associations remained significant after adjustment for traditional factors included in the CV risk equations in the overall population and in patients with normal renal function. The 8-iso-PGF22α cutoffs that best distinguished patients with high CV risk were 310 pg/mL for Fr-S and 264 pg/mL for ASCVD-S in the overall population, with significant differences between the groups divided by eGFR (all p<0.001). Conclusion. 8-iso-PGF2α may have a prognostic role in primary prevention of CV events in hypertensive patients, particularly in those with normal renal function.